China
Africa
Explore chapters and articles related to this topic
Role of Plant-Based Bioflavonoids in Combating Tuberculosis
Published in Megh R. Goyal, Durgesh Nandini Chauhan, Assessment of Medicinal Plants for Human Health, 2020
Alka Pawar, Yatendra Kumar Satija
Rifampicin (RIF) binds to beta RNA polymerase of bacteria and inhibits the RNA synthesis. It includes a set of antibacterial drugs and contains various derivatives viz., rifampicin, rifapentine, rifabutin, and rifalazil.3 Drug resistance is associated with mutation in 81bp region of rpoB gene, which encodes for beta RNA polymerase. INH and RIF with their derivatives are most common used drugs used for TB chemotherapy in combination with additional molecules.
Repositioning rifamycins for Mycobacterium abscessus lung disease
Published in Expert Opinion on Drug Discovery, 2019
Uday S. Ganapathy, Véronique Dartois, Thomas Dick
Given that rifabutin is resistant to oxidation, novel rifamycin derivatives should also incorporate structural features that block oxidation. Scaffolds in which the napthoquinone has a stable oxidation state may thus exhibit good potency against M. abscessus. For example, rifalazil also lacks a hydroquinone and is resistant to autoxidation [78]; its activity against M. abscessus, however, has yet to be determined. A better understanding of how rifamycin oxidation in M. abscessus (both via autoxidation and enzyme-mediated mechanisms) impacts potency is needed.
Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment
Published in Hospital Practice, 2018
Omar Abughanimeh, Ayman Qasrawi, Osama Kaddourah, Laith Al Momani, Mouhanna Abu Ghanimeh
Rifalazil is a third-generation rifamycin, which has a prolonged half-life and, thus, is administered once daily [6]. It has been studied as treatment for CDI in hamsters [71]. This drug, when used in a 5-day course, was superior to vancomycin [3].